Boronic ester and acid compounds, synthesis and uses

• US 6,066,730 A
• Filed: 05/26/1998
• Issued: 05/23/2000
• Est. Priority Date: 10/28/1994
• Status: Expired due to Term

• Current Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Original Assignee: ProScript, Inc. (Takeda Pharmaceutical Company Limited)
• Inventors: Adams, Julian, Grenier, Louis, Plamondon, Louis, Ma, Yu-Ting, Baevsky, Matthew, Stein, Ross
• Primary Examiner(s): Ramsuer, Robert W.
• Application Number:
  US09/085,404
• Time in Patent Office: 728 Days
• Field of Search: 544/69, 544/229, 546/13
• US Class Current: 544/69
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07F 5/025 Boronic and borinic acid compounds
• CPC Class Codes: C07F 5/04 Esters of boric acids
• CPC Class Codes: C07K 5/06 Dipeptides
• CPC Class Codes: C07K 5/06043 Leu-amino acid
• CPC Class Codes: C07K 5/06139 : with the first amino acid being heterocyclic
• CPC Class Codes: C07K 5/06191 : containing heteroatoms different from O, S, or N
• CPC Class Codes: C07K 5/0808 : the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
• CPC Class Codes: C07K 5/0827 : containing heteroatoms different from O, S, or N

Abstract

Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.

Claims

1. A compound having the formula:

##STR51## or a pharmaceutically acceptable salt thereof;

wherein P is an amino protecting group;

A is 1;

B¹ is CH;

X¹ is --C(O)--NH--;

X² is --C(O)--NH--;

R is hydrogen or alkyl;

R¹ is hydrogen, C_1-8 alkyl, C_3-10 cycloalkyl, C_6-10 aryl, or --CH₂ --R⁵, where the ring portion of said aryl can be optionally substituted;

R² is naphthylmethyl, pyridylmethyl or quinolinylmethyl;

R³ is C₄ alkyl;

R⁵ is one of C_6-10 aryl, C_6-10 ar(C_1-6)alkyl, C_1-6 alk(C_6-10)aryl, C_3-10 cycloalkyl, C_1-8 alkoxy or --W--R⁶, where W is a chalcogen and R⁶ is alkyl, where the ring portion of any of said aryl, aralkyl, or alkaryl can be optionally substituted; and

Z¹ and Z² are independently one of hydroxy, alkoxy, or aryloxy, or together Z¹ and Z² form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.

2. A compound of claim 1, wherein P is R⁷ --(O)-- or R⁷ --O--C(O)-- and R⁷ is alkyl, cycloalkyl, aryl or aralkyl.

3. A compound of claim 2, wherein P is acetyl, benzoyl, benzyloxycarbonyl or tert-butoxycarbonyl.

4. A compound of claim 1, wherein P is R⁷ --C(O)--, and R⁷ is quinolinyl, pyrazinyl, pyridyl, quinoxalinyl or N-morpholinyl.

5. A compound of claim 1, wherein R³ is isobutyl.

6. A compound of claim 1, wherein R² is naphthylmethyl.

8. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt or boronate ester thereof, and a pharmaceutically acceptable carrier or diluent.

9. A method for reducing the rate of muscle protein degradation in a cell comprising contacting said cell with a compound of claim 1.

10. A method for reducing the activity of NF-κ

B in a cell comprising contacting said cell with a compound of claim 1.

11. A method for reducing the rate of intracellular protein breakdown comprising contacting cells with a compound of claim 1.

12. A method of preventing or treating an inflammatory condition in a patient in need thereof, said method comprising administering to said patient a compound of claim 1.

7. N-Acetyl-L-leucine-β

-(1-naphthyl)-L-alanine-L-leucine boronic acid or a pharmaceutically acceptable salt or boronate ester therof.